Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Amicus Therapeutics (FOLD) over the last 16 years, with Q3 2025 value amounting to $19.1 million.

  • Amicus Therapeutics' Accounts Payables rose 4170.31% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year increase of 4170.31%. This contributed to the annual value of $12.9 million for FY2024, which is 1437.17% down from last year.
  • As of Q3 2025, Amicus Therapeutics' Accounts Payables stood at $19.1 million, which was up 4170.31% from $13.9 million recorded in Q2 2025.
  • Amicus Therapeutics' Accounts Payables' 5-year high stood at $32.1 million during Q2 2024, with a 5-year trough of $9.2 million in Q1 2024.
  • Its 5-year average for Accounts Payables is $18.0 million, with a median of $15.4 million in 2022.
  • The largest annual percentage gain for Amicus Therapeutics' Accounts Payables in the last 5 years was 13707.29% (2024), contrasted with its biggest fall of 6310.84% (2024).
  • Quarter analysis of 5 years shows Amicus Therapeutics' Accounts Payables stood at $21.5 million in 2021, then fell by 28.35% to $15.4 million in 2022, then fell by 1.9% to $15.1 million in 2023, then fell by 14.37% to $12.9 million in 2024, then soared by 47.55% to $19.1 million in 2025.
  • Its Accounts Payables stands at $19.1 million for Q3 2025, versus $13.9 million for Q2 2025 and $14.5 million for Q1 2025.